Replies to post #16178 on Synaptogenix Inc (SNPX)

[Babaji]

I am very excited about the synthetic usage in the upcoming (stating in the next few months) NIH funded trial, Project Number: 1R44AG066366-01

Stated objective:

The objective of this proposal is to directly test the long-term therapeutic benefit of the chronic bryostatin-1 (synthetic) treatment for the advanced AD patients. The proposed study will establish whether a 12-week treatment with synthetic bryostatin-1, through restoring synaptic functions and enhancing synaptic capacity in supporting cognitive challenges in addition to actions of anti-AD pathologies, will effectively produce long-term and effective improvements in cognition of the advanced AD patients. If the therapeutic effect is short-lived, a second treatment will be applied to reverse the cognitive decline after the end of the first 12-week treatment.